InvestSMART

The article you are trying to access does not exist, however, here are some articles you may be interested in.

Lumos Diagnostics Holdings Limited (ASX: LDX) - Announcements

- Current share price for LDX : $0.100

ASX company news and announcements for Lumos Diagnostics Holdings Limited (LDX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Lumos Diagnostics Holdings Limited (LDX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Lumos Diagnostics Holdings Limited (LDX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Lumos Diagnostics Holdings Limited (LDX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$97 Lumos expands WellStreet Urgent Care locations 14 Apr 2026 2:35PM $0.170 $0.100 fallen by 41.18%
$97 Change in substantial holding from RYD 14 Apr 2026 10:14AM $0.180 $0.100 fallen by 44.44%
$97 Lumos receives US$5m FebriDx milestone payment from PHASE 14 Apr 2026 9:13AM $0.170 $0.100 fallen by 41.18%
$97 Response to ASX Aware Letter 10 Apr 2026 5:31PM $0.175 $0.100 fallen by 42.86%
$97 Target Market Determination 10 Apr 2026 9:32AM $0.190 $0.100 fallen by 47.37%
$97 Prospectus 10 Apr 2026 9:31AM $0.190 $0.100 fallen by 47.37%
$97 SPP - Letter to Eligible Shareholders 10 Apr 2026 9:30AM $0.190 $0.100 fallen by 47.37%
$97 Application for quotation of securities - LDX 9 Apr 2026 12:10PM $0.200 $0.100 fallen by 50%
$97 Section 708A Cleansing Statement 9 Apr 2026 12:10PM $0.200 $0.100 fallen by 50%
$97 Application for quotation of securities - LDX 9 Apr 2026 12:06PM $0.200 $0.100 fallen by 50%
$97 Section 708A Cleansing Statement 9 Apr 2026 12:05PM $0.200 $0.100 fallen by 50%
$97 Lumos secures new contract manufacturing agreement 8 Apr 2026 9:45AM $0.210 $0.100 fallen by 52.38%
$97 Section 708A Cleansing Statement 2 Apr 2026 12:01PM $0.230 $0.100 fallen by 56.52%
$97 Application for quotation of securities - LDX 2 Apr 2026 12:00PM $0.230 $0.100 fallen by 56.52%
$97 Lumos receives largest FebriDx order to date 1 Apr 2026 10:47AM $0.230 $0.100 fallen by 56.52%
$97 Investor Briefing Invitation 27 Mar 2026 4:33PM $0.255 $0.100 fallen by 60.78%
$97 Investor Presentation 27 Mar 2026 10:13AM $0.265 $0.100 fallen by 62.26%
$97 Proposed issue of securities - LDX 27 Mar 2026 10:08AM $0.265 $0.100 fallen by 62.26%
$97 Proposed issue of securities - LDX 27 Mar 2026 10:08AM $0.265 $0.100 fallen by 62.26%
$97 Lumos completes $20m placement and launches SPP 27 Mar 2026 10:08AM $0.265 $0.100 fallen by 62.26%
$97 US FDA Grants CLIA Waiver for FebriDx 27 Mar 2026 10:08AM $0.265 $0.100 fallen by 62.26%
$97 Trading Halt 25 Mar 2026 9:21AM $0.265 $0.100 fallen by 62.26%
$97 Section 708A Cleansing Statement 5 Mar 2026 9:34AM $0.275 $0.100 fallen by 63.64%
$97 Application for quotation of securities - LDX 5 Mar 2026 9:32AM $0.275 $0.100 fallen by 63.64%
$97 1H FY26 Results Investor Presentation 3 Mar 2026 10:31AM $0.275 $0.100 fallen by 63.64%

51 - 75 of 557 results

Page 3 of 23

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.